0
Allergy and Airway |

Safety and Tolerability of Once-Daily Tiotropium Respimat Add-On to at Least ICS: Results From Five Phase III Trials in Adult Patients With Symptomatic Asthma FREE TO VIEW

Mark Vandewalker; Eli Meltzer; Michael Engel; Ralf Sigmund; Petra Moroni-Zentgraf; Huib Kerstjens
Author and Funding Information

Clinical Research of the Ozarks, Columbia, MO


Chest. 2014;146(4_MeetingAbstracts):1A. doi:10.1378/chest.1994482
Text Size: A A A
Published online

Abstract

SESSION TITLE: Asthma Posters I

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM

PURPOSE: Tiotropium Respimat®, a once-daily long-acting anticholinergic bronchodilator, has been shown to be an efficacious and well tolerated add-on to at least ICS in adult patients with symptomatic asthma. We present key safety data from five Phase III, randomized, double-blind, parallel-group trials that evaluated the efficacy and safety of once-daily tiotropium Respimat® as add-on to at least ICS versus placebo Respimat® in adult patients with symptomatic asthma.

METHODS: 2 × 48-week trials of tiotropium Respimat® 5 µg (PrimoTinA-asthma®: NCT00776984; NCT00772538) in patients on high-dose ICS (≥800 µg budesonide or equivalent) plus LABA; 2 × 24-week trials of tiotropium Respimat® 5 µg and 2.5 µg (MezzoTinA-asthma®: NCT01172808, NCT01172821) in patients on medium-dose ICS (400-800 µg budesonide or equivalent); 1 × 12-week trial of tiotropium Respimat® 5 µg and 2.5 µg (GraziaTinA-asthma®: NCT01316380) in patients on low-dose ICS (200-400 µg budesonide or equivalent).

RESULTS: 3476 patients were treated. The incidence of any adverse events was similar across treatment groups within each trial, with the majority being mild or moderate in severity. Adverse events reported by ≥5% of patients were similar across all treatment groups within each trial. Adverse events reported by ≥5% of patients across all treatment groups within each trial included asthma, decreased peak expiratory flow, nasopharyngitis, upper respiratory tract infection, headache, and bronchitis. Overall, a low frequency of serious adverse events was observed: PrimoTinA-asthma® tiotropium Respimat® 5 µg 8.1%, placebo Respimat® 8.8%; MezzoTinA-asthma® tiotropium Respimat® 5 µg 2.1%, tiotropium Respimat® 2.5 µg 2.3%, placebo Respimat® 2.7%; GraziaTinA-asthma® tiotropium Respimat® 5 µg 0.6%, tiotropium Respimat® 2.5 µg 0%, placebo Respimat® 0.6%. No deaths occurred.

CONCLUSIONS: Once-daily tiotropium Respimat® add-on to at least ICS is well tolerated and has a safety profile comparable to placebo Respimat® in adult patients with symptomatic asthma.

CLINICAL IMPLICATIONS: Once-daily tiotropium Respimat® may provide an alternative add-on therapy to at least ICS in adult patients with symptomatic asthma. Funding: Boehringer Ingelheim. Editorial assistance: Complete HealthVizion.

DISCLOSURE: Mark Vandewalker: Grant monies (from industry related sources): Research grant from Boehringer-Ingelheim Eli Meltzer: Grant monies (from industry related sources): Alcon, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, HRA, Kalypsys, Merck, Novartis, Ono, Proctor & Gamble, Rigel, Shionogi, Sunovion, Teva, Consultant fee, speaker bureau, advisory committee, etc.: Alcon, Alexza, AstraZeneca, Bausch + Lomb, Boehringer Ingelheim, Johnson & Johnson, Kalypsys, Meda, Merck, Mylan, Proctor & Gamble, Rigel, Sanofi, Sunovion, Teva Michael Engel: Employee: Boehringer-Ingelheim Ralf Sigmund: Employee: Boehringer-Ingelheim Petra Moroni-Zentgraf: Employee: Boehringer-Ingelheim Huib Kerstjens: Consultant fee, speaker bureau, advisory committee, etc.: From Boerhringer an d Pfizer, in relation to the work presented. As consultant, advisory baord member, and as principal investigator and recruiter., Consultant fee, speaker bureau, advisory committee, etc.: From Almirall, to my institution for consultancies, Consultant fee, speaker bureau, advisory committee, etc.: From Novartis, to my institution for consultancies

This abstract includes data from clinical trials of tiotropium in asthma. However, tiotropium is not approved for use in asthma and its safety and efficacy have not yet been established in asthma.


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543